Platforms
A mechanistic driven strategy based on unique designs of lipid structures
HighField Nano-Sized Lipid Structures
Highfield has developed novel immunoliposomes using its ADCplexTM, TCEplexTM and tLNPplexTM platforms.
The products are designed based on lipid self-assembly mechanisms to intergrade multiple functions, including targeting, immune modulating, chemotherapy and gene modification for improved safety, efficacy and quality.
The nano-sized lipid structures are biocompartible.
They travel in circulation to reach diseased tissues persistantly.
ADCplex™
Lipid-based Antibody Drug Complex
The ADCplex platform, with K1 the lead candidate, delivers toxic drugs into cancer cells.
The technology leverages the passive tumor targeting characteristics of lipid nanoparticles in combination with active tumor cell engagement. The toxic chemotherapeutic drugs are “locked up” until they are internalized by tumor cells.
The ADCplex structures are much like antibody drug conjugates (ADCs), but offer greater payload capacity and a different tumor tissue penetration mechanism than ADCs, allowing for greater payload uptake by cancer cells.
Upon modeling the tumor penetration and intracellular delivery process of our ADCplex immunoliposomes, we came up with the “golf cart” approach. The liposomes “escort” the payloads in a more efficient way than ADCs so there is a close to linear dose vs. intracellular delivery correlation. In this case, we can even combine two kinds of immunoliposomes carrying two different payloads and expect higher efficacy and low toxicity.
The versatility of the ADCplex structure makes it readily applicable to autoimmune diseases and other illnesses using different payloads.
TCEplex™
T Cell Engager Complex
The TCEplex platform, with HF50 the lead candidate, combines the antibody targeting effect with T cell engaging functions to treat cancer.
TCEplex is another showcase of our lipid based therapeutics design that uses lipid bilayer and physical forces to link antibody binding domains and payloads.
The lipid structure is fitted with two antibodies, one to engage T cells and the other to bind to receptors on cancer cells. In addition, an immune modulator is encapsulated inside the lipid structure to complement the immune clearance effect.
This lipid system represents a safer, more effective and less expensive alternative to traditional bispecific antibody drugs and CAR T therapies. HighField also is applying its TCEplex technology to treat other illnesses, such as autoimmune diseases.
tLNPplex™
Targeted Lipid Nanoparticle Complex
The tLNPplex platform, with HFG1 the lead candidate, enables applications of gene therapy to complex diseases well beyond treatment of genetic deficiencies, creating a next generation of gene-based therapeutics that are stable and provide long-term therapeutic effect.
We found that there are three LNP structures: emulsion-like LNPs (eLNPs), membrane-stabilized LNPs (mLNPs), and classic “bleb” structure LNPs (cLNPs). The size, surface property and stability of the LNPs affect their circulation, distribution and interaction with specific tissues and cells in vivo. Our unique membrane-stabilized LNPs (mLNPs) were developed to enable antibody conjugated lipid (TL) attachment for cell specific gene transfection.
English 
简体中文